These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 34027694)

  • 61. Adjuvant therapeutic decisions in elderly breast cancer patients: the role of chemotherapy in a retrospective analysis.
    Jueckstock J; Kasch F; Jaeger B; Schramm A; Janni W; Scholz C
    Arch Gynecol Obstet; 2015 Nov; 292(5):1101-7. PubMed ID: 25935195
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Impact of the 21-gene assay in decision-making during multidisciplinary breast meeting: A French experience].
    Dreyfus C; Ballester M; Gligorov J; Agranat P; Antoine M; Tengher I; Bricou A
    Gynecol Obstet Fertil; 2015 Dec; 43(12):780-5. PubMed ID: 26584893
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 64. 21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes.
    Tong Y; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Chen X; Shen K
    Sci Rep; 2019 Sep; 9(1):13123. PubMed ID: 31511599
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The impact of the 21-gene assay on adjuvant treatment decisions in oestrogen receptor-positive early breast cancer: a prospective study.
    Kuchel A; Robinson T; Comins C; Shere M; Varughese M; Sparrow G; Sahu A; Saunders L; Bahl A; Cawthorn SJ; Braybrooke JP
    Br J Cancer; 2016 Mar; 114(7):731-6. PubMed ID: 26954715
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Geriatric Assessment Predicts Survival and Competing Mortality in Elderly Patients with Early Colorectal Cancer: Can It Help in Adjuvant Therapy Decision-Making?
    Antonio M; Saldaña J; Carmona-Bayonas A; Navarro V; Tebé C; Nadal M; Formiga F; Salazar R; Borràs JM
    Oncologist; 2017 Aug; 22(8):934-943. PubMed ID: 28487465
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
    Dieci MV; Guarneri V; Zustovich F; Mion M; Morandi P; Bria E; Merlini L; Bullian P; Oliani C; Gori S; Giarratano T; Orvieto E; Griguolo G; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P;
    Oncologist; 2019 Nov; 24(11):1424-1431. PubMed ID: 31152079
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Use of adjuvant chemotherapy in hormone receptor-positive breast cancer patients with or without the 21-gene expression assay.
    Park SJ; Lee MH; Kong SY; Song MK; Joo J; Kwon Y; Lee EG; Han JH; Sim SH; Jung SY; Lee S; Lee KS; Park IH; Lee ES
    Breast Cancer Res Treat; 2018 Jul; 170(1):69-76. PubMed ID: 29516374
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Adjuvant chemotherapy and survival outcome in node-negative breast cancer with a 21-gene recurrence score of 26-30.
    Yang SP; Yao J; Zhou P; Lian CL; Wang J; Fang MX; Wu SG
    Future Oncol; 2021 Jun; 17(17):2183-2192. PubMed ID: 33605163
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancer.
    Goldstein DA; Mayer C; Shochat T; Reinhorn D; Moore A; Sarfaty M; Yerushalmi R; Goldvaser H
    Cancer Med; 2020 Jul; 9(13):4603-4612. PubMed ID: 32372569
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Preferred and Perceived Participation of Younger and Older Patients in Decision Making About Treatment for Early Breast Cancer: A Prospective Study.
    Hamelinck VC; Bastiaannet E; Pieterse AH; van de Velde CJH; Liefers GJ; Stiggelbout AM
    Clin Breast Cancer; 2018 Apr; 18(2):e245-e253. PubMed ID: 29275105
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.
    Levine MN; Julian JA; Bedard PL; Eisen A; Trudeau ME; Higgins B; Bordeleau L; Pritchard KI
    J Clin Oncol; 2016 Apr; 34(10):1065-71. PubMed ID: 26598746
    [TBL] [Abstract][Full Text] [Related]  

  • 73. First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.
    Dieci MV; Guarneri V; Giarratano T; Mion M; Tortora G; De Rossi C; Gori S; Oliani C; Merlini L; Pasini F; Bonciarelli G; Griguolo G; Orvieto E; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P
    Oncologist; 2018 Mar; 23(3):297-305. PubMed ID: 29133514
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Impact of Oncotype DX testing on adjuvant treatment decisions in patients with early breast cancer: a single-center study in the United Arab Emirates.
    Jaafar H; Bashir MA; Taher A; Qawasmeh K; Jaloudi M
    Asia Pac J Clin Oncol; 2014 Dec; 10(4):354-60. PubMed ID: 25243360
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Molecular and protein markers for clinical decision making in breast cancer: today and tomorrow.
    Harbeck N; Sotlar K; Wuerstlein R; Doisneau-Sixou S
    Cancer Treat Rev; 2014 Apr; 40(3):434-44. PubMed ID: 24138841
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer.
    Hannouf MB; Zaric GS; Blanchette P; Brezden-Masley C; Paulden M; McCabe C; Raphael J; Brackstone M
    Pharmacogenomics J; 2020 Feb; 20(1):27-46. PubMed ID: 31130722
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Biomarkers of neoadjuvant/adjuvant chemotherapy for breast cancer.
    Iwamoto T; Kajiwara Y; Zhu Y; Iha S
    Chin Clin Oncol; 2020 Jun; 9(3):27. PubMed ID: 32192349
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy.
    Sjöström M; Chang SL; Fishbane N; Davicioni E; Hartman L; Holmberg E; Feng FY; Speers CW; Pierce LJ; Malmström P; Fernö M; Karlsson P
    Clin Cancer Res; 2020 Jan; 26(1):171-182. PubMed ID: 31558478
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
    Bueno-de-Mesquita JM; van Harten WH; Retel VP; van 't Veer LJ; van Dam FS; Karsenberg K; Douma KF; van Tinteren H; Peterse JL; Wesseling J; Wu TS; Atsma D; Rutgers EJ; Brink G; Floore AN; Glas AM; Roumen RM; Bellot FE; van Krimpen C; Rodenhuis S; van de Vijver MJ; Linn SC
    Lancet Oncol; 2007 Dec; 8(12):1079-1087. PubMed ID: 18042430
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prospective Study Comparing Clinicians' and Cancer Patients' Estimates of Risk of Relapse and Toxicity with Adjuvant Chemotherapy.
    Calderon C; Jiménez-Fonseca P; Hernández R; Muñoz MDM; Martínez de Castro E; Higuera O; Ghanem I; Castelo B; Rogado J; Carmona-Bayonas A
    Cancer Invest; 2021 Sep; 39(8):589-596. PubMed ID: 34182858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.